Protein covariance networks reveal interactions important to the emergence of SARS coronaviruses as human pathogens

William P. Robins[1] and John J. Mekalanos[1]

[1]Department of Microbiology, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115

[1]Corresponding authors

Abstract

SARS-CoV-2 is one of three recognized coronaviruses (CoVs) that have caused epidemics or pandemics in the 21st century and that have likely emerged from animal reservoirs based on genomic similarities to bat and civet viruses. Here we report the analysis of conserved interactions between amino acid residues in all proteins encoded by SARS-CoV-related viruses. We identified pairs and networks of residue variants that exhibited statistically high frequencies of covariance with each other. While these interactions are likely key to both protein structure and other protein-protein interactions, we have also found that they can be used to provide a new computational approach (CoVariance-based Phylogeny Analysis) for understanding viral evolution and adaptation. Our data provide evidence that the evolutionary processes that converted a bat virus into human pathogen occurred through recombination with other viruses in combination with new adaptive mutations important to human infection.

Results and Discussion

The emergence of SARS-CoV and MERS-CoV as human pathogens is attributed to zoonotic infections in bats that transferred to civets and camels, respectively, while SARS-CoV-2 is similar to viruses isolated from both bats and pangolins implicating these species in the emergence of this historic virus (Al-Omari et al., 2019; Corman et al., 2014; Hu et al., 2017; Li, 2005; Wu et al., 2020; Zhang et al., 2020). The ~30kb genome size of all SARS-related CoVs render sequence alignment and pairwise distance methods effective for phylogenic studies and predicting the likely source of such coronaviruses (CoVs). While nucleic acid sequence-based phylogenies are informative they clearly have theoretical limitations. Thus, we focused on variations in protein sequence to understand CoV evolution and the key functional interactions that drive adaption to new hosts or that influence transmission and pathogenicity.

We selected the conserved CoV proteins called 1a/1b, Spike(S), 3a, E, M, and N from a set of 850 viral genomes (Supplemental table S1). The alignment resulted in a 9639 amino acid consensus sequence with only 2% of sites being gaps with low coverage and 2% with low sequence conservation

(Supplemental File F1). Because there are regions of diverged nucleotide identity in these viral genomes, our goal was to use encoded amino acid identity to initially estimate phylogeny and then integrate that analysis with the identification of covariant residues within these six core viral proteins. Both SARS-CoV and SARS-CoV-2 are represented by a large collection of independent isolates from previous and current epidemics as well as from variants selected during passage in various laboratories (Supplemental Table S1) (Elbe and Buckland-Merrett, 2017). Similar to nucleic acid sequence-based analyses, our constructed phylogeny (Supplemental Figure S1) shows that SARS-CoV is closely related to CoVs found in civets and groups of bat CoVs that were previously suggested as likely ancestors (Li, 2005; Song et al., 2005). In contrast, SARS-CoV-2 is a close relative to bat CoV RATG13 and also more similar to two bat CoVs, SZXC21 and SZC45, than other bat CoVs (Li, 2005; Paraskevis et al., 2020; Song et al., 2005). Five recently isolated pangolin CoVs identified as closely related to SARS-CoV-2 are also related to these three bat CoVs (Zhang et al., 2020) and our protein-based analysis supports this conclusion. Thus, amino acid sequence-based analysis indicates that both bat and pangolin CoVs share likely represent probable common ancestors of SARS-CoV-2 (Xia, 2020).

To survey the frequency of covariance among CoVs, we extracted pairs and groups (here designated 'Clusters') of covarying amino acid residues and organized these using a correlating tandem model that was set at different purity thresholds between 0.8 and 1.0. We selected a stringent purity threshold (0.96) to reduce noise based on our sampling size (Supplemental Table S2). We then applied force-directed mapping algorithms to visualize the relationships between these clusters of covarying residues and the CoV isolates from which they were derived (Jacomy et al., 2014). This graphing technique simulates repulsion between nodes (residues, clusters, and genomes) as well as attraction between edges (links between nodes) and then plots them to minimize both complexity (fewer crossed edges) and to reduce edge lengths in two dimensions. Nodes are force-directed according to hierarchy and this orients these based on sequential linkage (edges) to clusters and then residues. Remarkably, we find that force-directed mapping of the linkage of covariance clusters to viral genomes readily organized all CoV isolates into groups that were consistent with phylogenic analysis (Figure 1 and Supplemental Figure S1). Thus, related genomes are forced into groupings in the middle of the graph surrounded by related clusters that are then flanked by networks of covarying residues. Furthermore, we provide every cluster and all residues identities by gene, genome, and host in a table and Gephi force map file (Supplemental Table S3 and Supplemental File S1) as well as an interactive website (https://sarscovresidues2.com/). We call this collective approach to understanding viral evolution 'CoVariance based Phylogeny Analysis (CoVPA)' and propose that it provides novel insights into the evolutionary origins of viral genomes.

Some covariant clusters are ubiquitous to the entire grouping of viruses while others are exclusive to only one strain. We binned these clusters to compare covarying residues that are restricted to isolates from a given host mammalian species or a given group of CoVs. By comparing networks of clusters of covarying residues between distinct groupings, we could identify clusters that are restricted to various combinations of bat, civet, pangolin, and human CoV isolates. Thus, this annotated comprehensive dataset identifies all distinct residue identities that strongly covary in each CoV protein and the distribution of these in CoVs that include the human pathogens SARS-CoV and SARS-CoV-2. In its entirety, this provides a novel dataset that can be accessed through an interactive website (https://sarscovresidues2.com/) which allows one to explore the relatedness of CoV isolates based on conserved amino acid interactions that likely contribute to structure, protein-protein interactions, or biological function that multiple proteins drive interactively.

Both the civet and bat CoVs were previously identified as the closest relatives of SARS-CoV (Hu et al., 2017; Song et al., 2005) and these are positioned immediately adjacent to SARS-CoV in our force-directed network. There are a few residues that are different between Civet CoVs (Cluster 26) and SARS-CoV (Cluster 65), but 103 residues are uniquely shared by both (Cluster 182). This supports previous findings that few genomic changes occurred between civet and the human-adapted SARS-CoV and that the majority of these polymorphisms likely arose during the initial transition from bats to civets (Song et al., 2005). We conclude that these three clusters include residue identities that separate closely related bat CoVs from those enriched by passage and adaptation through other host species. The majority of these residues are in 1a/1b polyproteins, S, and 3a while covariance in E, M, and N is virtually absent.

Analogous to the civet and SARS-CoV relationship, three bat CoVs including RATG13 and five pangolin CoVs are all closely related to SARS-CoV-2 and are thus positioned in proximity in the network mapping because these share a significant number of covariant residues and clusters. In total, 10 clusters contain 1231 uniquely covarying residues specific to SARS-CoV-2 and the three most closely related bat CoVs. Covariant residues are highly represented in gene 1a encoding non-structural proteins (nsp1-nsp4), as well as the S protein and viroporin 3a (Supplemental Table S5). We surmise that these enriched covariant residues could include those that facilitated transmissibility into humans. Covariant residues are least represented in the RNA replication proteins, viroporin E, and membrane protein M. We did not find any cluster exclusive to all SARS-CoV-2 strains apart from those emerging in clinical isolates (Clusters 5 and 23) and instead find common overlapping clusters of covariant residues. For example, SARS-CoV-2 covariant residues are found to overlap with RATG13 (Cluster 183), or with RATG13 and pangolin CoVs (Cluster 194), or with the three bat viruses RATG13/COVCZ45/COVXC21 (Cluster 190), or with these

three bat CoVs and with pangolin CoVs (Cluster 197). As these CoVs share significant nucleotide similarity with another, this is not surprising; however, our covariance analysis also reveals key diverging features for the SARS-CoV-2 group that likely have biological significance. For example, there are covariant residues in the SARS-CoV-2 Spike (S protein) that reside in its receptor binding domain (RBD), its amino-terminal domain (NTD), and in a structural region proximal to the furin cleavage site in its C-terminal domain (CTD). These SARS-CoV-2 covariant residues are likely key to the adaptation of this virus to new host species (see below).

We next focused on determining the covarying residues that allowed SARS CoV-2 to emerge as a human pathogen by passage through intermediate hosts. To demonstrate the results of this analysis, we graphically show the stepwise progression and location of SARS-CoV-2 covariant clusters that overlap with those found in 48 bat CoVs and its related bat isolate, RATG13 (Figure 2A, 2B, Supplemental Table S4). We plotted all covariant residue positions across multiple groups of CoV genomes to map their locations at the gene product level. The largest density of covarying residues in this progression to SARS-CoV-2 maps to both the NTD and RBD subdomains of S protein and the 3a viroporin protein. We conclude that enriched covariance networks between S and 3a allowed certain CoV isolates to adapt to growth in intermediary hosts and ultimately humans.

The role of covariant residues distinctly enriched in a specific host may be important in the context of adaption and infection. To separate such 'restricted' variants that are unique to CoVs from different species, we binned groups of covariants and then compared their mapped locations on CoV genomes (Figure 2B). Those classified as 'restricted' are found in clusters linked to specific groups and absent in other groups. Surprisingly both bat- and pangolin-restricted covariants are represented in distinct regions of the genome; for example, bat restricted residues are primarily located in nonstructural proteins encoded in 1b (corresponding to the 2'O-Mtase, NendoU, and ExoN gene products) and enriched in 3a and N, but not S or M. Clearly SARS-CoV-2 covariant residues belong to clusters linked to bat CoVs, but we found residues that are linked to this virus which are absent in other restricted categories (see below).

A large section in gene 1a (~3000 AA, nsP1-nsP4) is unique to SARS-CoV-2 and distinct from the rest of the genome based on our covariance analysis. These contextual differences would not be readily apparent using standard nucleic acid-based single nucleotide polymorphism analyses. The identity and network of covariant residues in this region are unique based on matching mutations to those in bat viruses including those most similar such as RATG13 suggesting that this genomic region in SARS-CoV-2 experienced different selective pressures and evolutionary history (Figure 2A and 2B). The 3'-boundary of this region is aligned to a recombinational hotspot (Tagliamonte et al., 2020) and this suggests that

hybridization of different CoV isolates likely led to the emergence of SARS-CoV-2. Though this region of SARS-CoV-2 is most similar to RATG13, the divergence of covariance residues between bat and pangolin CoVs here provides strong evidence that parts of SARS-CoV-2 emerged from an independent distinct source (Figure 2C).

In contrast to host-restricted covariant clusters, others are conserved covarying residues in other CoVs. For example, the Enriched Conserved A group contains residues that align in more than one independent category (Figure 2A and 2C); these enriched covariant groups include residues that are part of large networks of covarying residues (for example, in the nsp1-nsp4 region). This particular group was found to be also densely enriched in the NTD and RBD of the S protein, in much of 3a, and in both the CTD and NTD domains in N. The networks of covariant residues in the S protein may provide plasticity in protein domains important for receptor recognition and possibly also escape from antibody responses given that the same regions are rich in dominant neutralizing epitopes (He et al., 2005; Qiu et al., 2005).

We examined the distribution and possible roles for the SARS-CoV-2 residues by mapping these to domains in the S protein using the structural information present in the recently solved SARS-CoV-2 S protein trimer PDB file (Walls et al., 2020). In line with bat COVs, covariant residues in the S protein of SARS-CoV-2 are densely represented in both its NTD (residues 1- 330) and its RBD (residues 333-527) (Supplemental Table S5). This includes residues between 438 and 506 that are part of the RBD interface with the ACE-2 receptor and also those between 333 and 526 that are thought to help stabilize the beta-sheet and short connecting helices and loops that form the core of the RBD (Lan et al., 2020). Between 438 and 510 we identify 7 of the 16 residues shown to interact directly with ACE-2 (Lan et al., 2020) are covariant (Supplemental Figure S2). As covariance analysis detects residues that change with others, nearly all (6 of 7) are residues that differ between SARS-CoV and SARS-CoV-2. When aligned to known SARS-CoV RBD contacts with 80R, a potent neutralizing monoclonal antibody that has been co-crystalized with the S trimer (Hwang et al., 2006), we found that 13 of 19 residues contacted by 80R are covariants that differ between both SARS-CoV and SARS-CoV-2 (Lan et al., 2020). Notably, though much of S is highly conserved in structure and many CoVs share ACE-2 as a common receptor, it has been suggested that residues in the RBD-ACE2 interface between SARS-CoV and SARS-CoV-2 are distinct enough to have arose by convergent evolution (Lan et al., 2020). Our analysis suggests that covariant residues in the NTD likely influence the biological properties of the S protein such as receptor binding specificity, membrane fusion activity, or its ability to escape neutralizing antibodies (see below).

To examine how the observed covariance compares to enriched mutations in the current epidemic, we examined 13,611 clinical strains sequenced since the emergence of the human epidemic

from the GISAID database (Elbe and Buckland-Merrett, 2017). We identified the covariant residue pairs and clusters most highly represented in clinical isolates and find these form small closed networks within and between proteins (Supplemental Figure 3A, Supplemental Table S6). These networks include some of the most abundant polymorphisms previously identified such 614 G/D in the S protein and 336 P/L in RdRp protein (Pachetti et al., 2020). Several residues located in the same small exposed flexible loop domain with 614 G/D are predicted to be covariant in our 850 strains with residues in viroporin 3a as well as other residues in the S protein located between its RBD and its furin protease cleavage site (Supplemental Figure 3B). The 3a and E viroporins of SARS-CoV are thought to be a K^+ and Ca^{++} efflux channels and it is interesting that furin is proteolytically activated by these cations (Izidoro et al., 2010; Molloy et al., 1992). Furin cleavage of the S protein trimer is strongly implicated in its activation for membrane fusion events (Coutard et al., 2020). In this regard, we find residue 614 G/D maps near the furin cleavage site in the S protein structure suggesting that 3a may be interacting with S during the process that leads to S cleavage and activation of membrane fusion. 3a and S proteins have been found to form a complex but the nature of this interaction is still unknown at the structural level (Shen et al., 2005; Tan, 2005; Tan et al., 2004). Curiously residues in this exposed loop of the S protein that encompasses 614 G/D are found to also covary with residues in the NTD of the S protein and distinct domains of 3a suggesting there is an evolutionary relationship between the 3a protein and S domains proximal to the furin cleavage site and its NTD.

Our observed covariance in the 3a viroporin was mapped to predicted functional domains of the S protein (Supplemental S3B, S4A). The 3a protein of SARS-CoV is predicted to assemble as both a homodimer and a tetramer that form a membrane channel (viroporin) in the cell and possibly the viral particle membrane (Ito et al., 2005; Lu et al., 2006). We noted covariance in distinct separate domains of 3a. There are covariant residues within a more variable NTD region (the first 30 residues of 3a) which is predicted to be surface-exposed as well as in other predicted extracellular and cytoplasmic loops (Supplemental Figure S4A). Antibodies to 3a and its N-terminal ectodomain from convalescent-phase SARS-CoV patients are commonly found (Qiu et al., 2005; Zhong, 2006) and the covariant residues that map here overlaps with a hypervariable region predicted to be more antigenic (Supplemental Figure S4B, S4C, S4D). We also identified a cluster of covariable residues in the CTD between 168 and 189; there is no role for this subdomain though it partially overlaps between residues 160 to 173 with a predicted cytoplasmic domain that contain putative intracellular protein sorting and trafficking motifs (Huang et al., 2006; Tan et al., 2004). In addition to a role in intracellular vesicle formation through interactions with Caveloin-1, the 3a viroporin of SARS-CoV protein is known to cause activation of the NLRP3

inflammasome, NF-kB activation, and chemokine induction as well as efficient viral release from infected cells (Castaño-Rodriguez et al., 2018; Chen et al., 2019; Freundt et al., 2010; Lu et al., 2006; Padhan et al., 2007). Thus identifying 3a as a hotspot for covariance and mutational selection may have relevance to the severe inflammation seen in COVID-19 disease and suggests that the 3a protein is a potential new target to consider for SARS-CoV-2 immunoprophylaxis.

The mutational history of genes are seldom random throughout evolution and display biases in regard to purine or pyrimidine substitutions that may reflect selective pressures such as polymerase fidelity, codon usage, and functionality of encoded gene products (reviewed by Lyons and Lauring, 2017). We wondered whether these biases might provide further evidence of the selective pressures experienced by covariant residues during the evolutionary histories of SARS CoV virus families. We measured the frequency of transition (purine-purine, pyrimidine-pyrimidine) and transversion (purine-pyrimidine) signal nucleotide polymorphisms (SNPs) between SARS-CoV-2, RATG13, and one of the closely related pangolin genomes analyzed in this work, PanCoV-GX-PL4, and found a bias against transversions that has also been noted in another study (Lam et al., 2020). The frequency of this bias (ratio of transition to transversion mutations) between the genomes of SARS-CoV-2 and RATG13 was approximately 2.0; in contrast, when comparing these two CoVs to PanCoV-GX-PL4 this bias was 7.5 (Figure 3). We interpret this result as evidence for the very recent evolutionary divergence between SARS-CoV-2 and RATG13 while PanCoV-GX-PL4 is clearly more evolutionarily distant relative to RATG13 and SARS-CoV-2.

Though the rate of SNP accumulation across the 30Kb genomes appears at a gross level to be linear, there are regions in genes where SNPs are densely represented relative to other regions. In the RBD of the S protein, a region we found is enriched for covariant residues, the frequency of transversion SNPs exceeds that of transition SNPs (Figure 3b). This 8.3-fold change in the ratio of transition to transversion, 7.5-fold to 0.90-fold, within this region encoding the RBD involves many codons encoding covariant residues. For example, 12 of 16 residues that changed in this region are in covariant residues in SARS-CoV-2 and many of these have accumulated 2 to 3 SNPs. Furthermore, non-covariant residue 483, a codon eabsent in SARS-CoV, is found to differ at all 3 codon positions as transversion SNPs when SARS-CoV-2 is compared to RATG13 and PanCoV-GX-PL.

The differences in the RBD of the S proteins of SARS-CoV-2 compared to RATG13, and pangolin viruses such as PCoV_GX-P4L has been previously attributed to recombination events that occurred between related ancestral viruses (Huang et al., 2020; Li et al., 2020; Zhang et al., 2020). However, we show here that the RBD of SARS-CoV and SARS-CoV-2 possess a pattern of conserved

covariant residues (Supplemental Figure S2), that were likely evolved in both these viruses under selection pressures that cannot be easily attributed to recombination alone. The inherent diversity of covariant residues identified in this analysis is demonstrated by the observation that only one covariant residue (N487 of the S protein) is also conserved in identity between SARS-CoV and SAR-CoV-2 (Supplemental Figure S2). Of the 16 residues in SARS-CoV shown to interact with the human ACE-2 receptor (Lan et al., 2020), 7 are covariant residues and an additional 5 are adjacent to covariant positions. These residues are predicted to covary with others in the RBD and residues primarily within S and 3a in both SARS-CoV and SARS-CoV-2. We hypothesize that the purifying selection imposed by these and other covariant networks resulted in the enhanced selection of radical changes in the covariant residues in the RBD of SARS CoV-2 that we observed. Thus, the observed co-variability of residues in the NTD and RBD of S as well as within the 3a protein is more easily explained by selective processes that can drive mutations in multiple sites within the same or different proteins rather than simple recombination events that would produce dramatic but uncoordinated changes in the structure of proteins.

Though we present covariance networks with numerous residues in SARS-CoV-2, there are a few small clusters identified in this work that likely reveal host-adaptation of CoVs. For example, Cluster 62 identifies 5 residues that emerged in SARS-CoV during its further passage and adaptation in the mouse model. In the context of human CoV diseases, we also identified one covariance network of eight residues in the S protein (Cluster 126) found only in SARS-COV and SARS SARS-COV-2 and the most closely related civet, pangolin, and bat CoVs (Supplemental Figure S5A, S5B). Though some of these residues are missing from the available models of the Spike trimers from both SARS-CoV and SARS-CoV-2, we find residues Q23, H66, and V213 are proximal to one another when comparing the tertiary NTD structures of both (Supplemental Figure S5B, S5C). The relative position of two other covariant residues L54 and M153 in the NTD is difficult to determine in that they reside within disordered and exposed regions in the cryo-EM S trimer reconstructions of SARS-CoV and SARS-CoV-2. There are no known interactions or roles for these protruding NTD regions of the S trimers. Because the NTD of the S protein is especially enriched in covariant residues, we propose that host- or immune-driven selective pressure has occurred within this subdomain. In combination, covariant residues in S protein appear to have emerged independently and are enriched in viruses that caused two independent pandemics suggesting they are particularly important to human infection.

Previously covariant network analysis applied to other RNA and DNA viruses demonstrates observed covariance in viruses is often not an artifact of chance and likely influenced by imposed pressure, structure, and selection, including those provided by therapeutics (Aurora et al., 2009; Donlin et

al., 2012; Sruthi and Prakash, 2019). Coevolving residues for large orthologous groups of proteins have also been useful in predicting structure (de Juan et al., 2013) and protein-protein interactions (Kamisetty et al., 2013) that are targeted for drug interference. In the present study, we identified networks of co-varying amino acid residues in proteins encoded by nearly 13,600 CoV isolates. Because these interactions can be in theory critical to the CoV family of viruses based on their conservation in the evolution and adaption of these viruses to humans, we propose that they could define novel antigen and drug targets for CoV-related viruses. These targets are uniquely valuable because they are likely under strong selective pressure at two or more amino acid sites in one or more proteins; this property will make it less likely for a virus to mutant to escape immune responses or anti-viral drugs directed at protein sites enriched in such covariant-related targets. Finally, our data also provide evidence and a novel perspective not readily apparent in standard sequence alignment analysis for new adaptive recombination events and mutations that likely drove the emergence of SARS-CoV-related viruses into the human host. These insights could inform preparedness through therapeutic and vaccine development, as well as public health policy.

Methods

Genome and protein sequences were downloaded from available NCBI and GISAID public databases. All genomes and accession numbers are provided in Supplemental Table S1. Protein sequences for genes in 1a,1b, Spike, 3a, E, M, and N were concatenated and aligned using CLC Bio Workbench (v8) for the 850 genomes using a gap open cost of 2.0 and a gap extension cost of 1.0 in very accurate mode and with MAFFT for the clinical SARS-CoV-2 strain using the default FFT-NS-2 setting (CLC-Bio Workbench 8, Nakamura et al., 2018). 13,611 clinical strains available on May 10, 2020 with significant contiguous coverage over the reference genes (>95%) were kept in the alignment. For Maximum Likelihood Phylogeny, we applied a WAG protein substitution model to our alignment and performed bootstrap analysis using 1000 replicates.

Pairwise and multiple residue covariance and scored were predicted using FastCov (Shen and Li, 2016). We set a purity score (0.96) for stringency cutoffs, but for clarity a raw table of predicted covariants is provided as Supplemental Table S2. This allowed binning of clusters and respective strains for Force Mapping in Gephi using the Multigravity ForceAtlas 2 setting and comparison of covariant residues based on clusters and strains (Jacomy et al., 2014). All clusters, strains, and residues are tabulated in Supplemental Table S3.

Clusters and residues were mapped in Gephi using the MultiGravity ForceAtlas 2 algorithm and this file is provided (Supplemental File F1) (Jacomy et al., 2014). The JavaScript Sigma.js library was used to export this as an interactive website.

Residues in Spike were mapped onto the PDB structure for Spike (6VXX.pdb and 6ACC.pdb) using PyMol (v.2.3.4) (PyMol, Song et al., 2018; Walls et al., 2020). Arpeggio was used to calculate interacting residues in the PDB file (Jubb et al., 2017). Circular graphing of key collections of residues was done using Circos (Krzywinski et al., 2009). Epitope mapping in the 3a NTD 44 amino acids was accomplished using BepiPred-2.0 (Jespersen et al., 2017)

Acknowledgements

This work was supported by National Institutes of Health Grant AI-018045-JJM. We would like to thank Matthew K. Waldor for his insight, perspective, and discussions about our analysis during the preparation of this manuscript.

Bibliography

Al-Omari, A., Rabaan, A.A., Salih, S., Al-Tawfiq, J.A., Memish, Z.A., 2019. MERS coronavirus outbreak: Implications for emerging viral infections. Diagn. Microbiol. Infect. Dis. 93, 265–285. https://doi.org/10.1016/j.diagmicrobio.2018.10.011

Aurora, R., Donlin, M.J., Cannon, N.A., Tavis, J.E., Group, the V.-C.S., 2009. Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. J. Clin. Invest. 119, 225. https://doi.org/10.1172/JCI37085

Castaño-Rodriguez, C., Honrubia, J.M., Gutiérrez-Álvarez, J., DeDiego, M.L., Nieto-Torres, J.L., Jimenez-Guardeño, J.M., Regla-Nava, J.A., Fernandez-Delgado, R., VerdiaBáguena, C., Queralt-Martín, M., Kochan, G., Perlman, S., Aguilella, V.M., Sola, I., Enjuanes, L., 2018. Role of Severe Acute Respiratory Syndrome Coronavirus Viroporins E, 3a, and 8a in Replication and Pathogenesis. mBio 9, e02325-17. https://doi.org/10.1128/mBio.02325-17

Chen, I.-Y., Moriyama, M., Chang, M.-F., Ichinohe, T., 2019. Severe Acute Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 Inflammasome. Front. Microbiol. 10. https://doi.org/10.3389/fmicb.2019.00050

CLC Genomics Workbench 20.0 (https://digitalinsights.qiagen.com)

Corman, V.M., Ithete, N.L., Richards, L.R., Schoeman, M.C., Preiser, W., Drosten, C., Drexler, J.F., 2014. Rooting the Phylogenetic Tree of Middle East Respiratory Syndrome Coronavirus by Characterization of a Conspecific Virus from an African Bat. J. Virol. 88, 11297. https://doi.org/10.1128/JVI.01498-14

Coutard, B., Valle, C., de Lamballerie, X., Canard, B., Seidah, N.G., Decroly, E., 2020. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 176, 104742. https://doi.org/10.1016/j.antiviral.2020.104742

de Juan, D., Pazos, F., Valencia, A., 2013. Emerging methods in protein co-evolution. Nat. Rev. Genet. 14, 249–261. https://doi.org/10.1038/nrg3414

Donlin, M.J., Szeto, B., Gohara, D.W., Aurora, R., Tavis, J.E., 2012. Genome-Wide Networks of Amino Acid Covariances Are Common among Viruses. J. Virol. 86, 3050–3063. https://doi.org/10.1128/JVI.06857-11

Elbe, S., Buckland-Merrett, G., 2017. Data, disease and diplomacy: GISAID's innovative contribution to global health. Glob. Chall. Hoboken NJ 1, 33–46. https://doi.org/10.1002/gch2.1018

Freundt, E.C., Yu, L., Goldsmith, C.S., Welsh, S., Cheng, A., Yount, B., Liu, W., Frieman, M.B., Buchholz, U.J., Screaton, G.R., Lippincott-Schwartz, J., Zaki, S.R., Xu, X.-N., Baric, R.S., Subbarao, K., Lenardo, M.J., 2010. The Open Reading Frame 3a Protein of Severe Acute Respiratory Syndrome-Associated Coronavirus Promotes Membrane Rearrangement and Cell Death. J. Virol. 84, 1097. https://doi.org/10.1128/JVI.01662-09

He, Y., Lu, H., Siddiqui, P., Zhou, Y., Jiang, S., 2005. Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Contains Multiple Conformation-Dependent Epitopes that Induce Highly Potent Neutralizing Antibodies. J. Immunol. 174, 4908. https://doi.org/10.4049/jimmunol.174.8.4908

Hu, B., Zeng, L.-P., Yang, X.-L., Ge, X.-Y., Zhang, W., Li, B., Xie, J.-Z., Shen, X.-R., Zhang, Y.-Z., Wang, N., Luo, D.-S., Zheng, X.-S., Wang, M.-N., Daszak, P., Wang, L.-F., Cui, J., Shi, Z.-L., 2017. Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. PLOS Pathog. 13, e1006698. https://doi.org/10.1371/journal.ppat.1006698

Huang, C., Narayanan, K., Ito, N., Peters, C.J., Makino, S., 2006. Severe Acute Respiratory Syndrome Coronavirus 3a Protein Is Released in Membranous Structures from 3a Protein-Expressing Cells and Infected Cells. J. Virol. 80, 210. https://doi.org/10.1128/JVI.80.1.210-217.2006

Huang, J.-M., Jan, S.S., Wei, X., Wan, Y., Ouyang, S., 2020. Evidence of the Recombinant Origin and Ongoing Mutations in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). bioRxiv 2020.03.16.993816. https://doi.org/10.1101/2020.03.16.993816

Hwang, W.C., Lin, Y., Santelli, E., Sui, J., Jaroszewski, L., Stec, B., Farzan, M., Marasco, W.A., Liddington, R.C., 2006. Structural Basis of Neutralization by a Human Anti-severe Acute Respiratory Syndrome Spike Protein Antibody, 80R. J. Biol. Chem. 281, 34610–34616. https://doi.org/10.1074/jbc.M603275200

Ito, N., Mossel, E.C., Narayanan, K., Popov, V.L., Huang, C., Inoue, T., Peters, C.J., Makino, S., 2005. Severe Acute Respiratory Syndrome Coronavirus 3a Protein Is a Viral Structural Protein. J. Virol. 79, 3182. https://doi.org/10.1128/JVI.79.5.3182-3186.2005

Izidoro, M.A., Assis, D.M., Oliveira, V., Santos, J.A.N., Juliano, M.A., Lindberg, I., Juliano, L., 2010. Effects of magnesium ions on recombinant human furin: selective activation of hydrolytic activity upon substrates derived from virus envelope glycoprotein. Biol. Chem. 391, 1105–1112. https://doi.org/10.1515/bc.2010.114

Jacomy, M., Venturini, T., Heymann, S., Bastian, M., 2014. ForceAtlas2, a Continuous Graph Layout Algorithm for Handy Network Visualization Designed for the Gephi Software. PLoS ONE 9, e98679. https://doi.org/10.1371/journal.pone.0098679

Jespersen, M.C., Peters, B., Nielsen, M., Marcatili, P., 2017. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Research 45, W24. https://doi.org/10.1093/nar/gkx346

Jubb, H.C., Higueruelo, A.P., Ochoa-Montaño, B., Pitt, W.R., Ascher, D.B., Blundell, T.L., 2017. Arpeggio: A Web Server for Calculating and Visualising Interatomic Interactions in Protein Structures. Comput. Resour. Mol. Biol. 429, 365–371. https://doi.org/10.1016/j.jmb.2016.12.004

Kamisetty, H., Ovchinnikov, S., Baker, D., 2013. Assessing the utility of coevolution-based residue–residue contact predictions in a sequence- and structure-rich era. Proc. Natl. Acad. Sci. 110, 15674. https://doi.org/10.1073/pnas.1314045110

Krzywinski, M.I., Schein, J.E., Birol, I., Connors, J., Gascoyne, R., Horsman, D., Jones, S.J., Marra, M.A., 2009. Circos: An information aesthetic for comparative genomics. Genome Res. https://doi.org/10.1101/gr.092759.109

Lam, T.T.-Y., Shum, M.H.-H., Zhu, H.-C., Tong, Y.-G., Ni, X.-B., Liao, Y.-S., Wei, W., Cheung, W.Y.-M., Li, W.-J., Li, L.-F., Leung, G.M., Holmes, E.C., Hu, Y.-L., Guan, Y., 2020. Identification of 2019-nCoV related coronaviruses in Malayan pangolins in southern China. bioRxiv 2020.02.13.945485. https://doi.org/10.1101/2020.02.13.945485

Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., Wang, X., 2020. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. https://doi.org/10.1038/s41586-020-2180-5

Li, W., 2005. Bats Are Natural Reservoirs of SARS-Like Coronaviruses. Science 310, 676–679. https://doi.org/10.1126/science.1118391

Li, X., Giorgi, E.E., Marichannegowda, M.H., Foley, B., Xiao, C., Kong, X.-P., Chen, Y., Gnanakaran, S., Korber, B., Gao, F., 2020. Emergence of SARS-CoV-2 through recombination and strong purifying selection. Sci Adv eabb9153. https://doi.org/10.1126/sciadv.abb9153L

Lyons, D.M., Lauring, A.S., 2017. Evidence for the Selective Basis of Transition-to-Transversion Substitution Bias in Two RNA Viruses. Molecular Biology and Evolution 34, 3205–3215. https://doi.org/10.1093/molbev/msx251

Lu, W., Zheng, B.-J., Xu, K., Schwarz, W., Du, L., Wong, C.K.L., Chen, J., Duan, S., Deubel, V., Sun, B., 2006. Severe acute respiratory syndrome-associated coronavirus 3a protein forms an ion channel and modulates virus release. Proc. Natl. Acad. Sci. 103, 12540. https://doi.org/10.1073/pnas.0605402103

Molloy, S.S., Bresnahan, P.A., Leppla, S.H., Klimpel, K.R., Thomas, G., 1992. Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen. J. Biol. Chem. 267, 16396–16402.

Nakamura, T., Yamada, K.D., Tomii, K., Katoh, K., 2018. Parallelization of MAFFT for largescale multiple sequence alignments. Bioinformatics 34, 2490–2492. https://doi.org/10.1093/bioinformatics/bty121

Pachetti, M., Marini, B., Benedetti, F., Giudici, F., Mauro, E., Storici, P., Masciovecchio, C., Angeletti, S., Ciccozzi, M., Gallo, R.C., Zella, D., Ippodrino, R., 2020. Emerging SARSCoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. J. Transl. Med. 18, 179. https://doi.org/10.1186/s12967-020-02344-6

Padhan, K., Tanwar, C., Hussain, A., Hui, P.Y., Lee, M.Y., Cheung, C.Y., Peiris, J.S.M., Jameel, S., 2007. Severe acute respiratory syndrome coronavirus Orf3a protein interacts with caveolin. J. Gen. Virol. 88, 3067–3077. https://doi.org/10.1099/vir.0.82856-0

Paraskevis, D., Kostaki, E.G., Magiorkinis, G., Panayiotakopoulos, G., Sourvinos, G., Tsiodras, S., 2020. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect. Genet. Evol. 79, 104212. https://doi.org/10.1016/j.meegid.2020.104212

Pymol. The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC.

Qiu, M., Shi, Y., Guo, Z., Chen, Z., He, R., Chen, R., Zhou, D., Dai, E., Wang, X., Si, B., Song, Y., Li, J., Yang, L., Wang, Jin, Wang, H., Pang, X., Zhai, J., Du, Z., Liu, Y., Zhang, Y., Li, L., Wang, Jian, Sun, B., Yang, R., 2005. Antibody responses to individual proteins of SARS coronavirus and their neutralization activities. Microbes Infect. 7, 882–889. https://doi.org/10.1016/j.micinf.2005.02.006

Shen, S., Lin, P.-S., Chao, Y.-C., Zhang, A., Yang, X., Lim, S.G., Hong, W., Tan, Y.-J., 2005. The severe acute respiratory syndrome coronavirus 3a is a novel structural protein. Biochem. Biophys. Res. Commun. 330, 286. https://doi.org/10.1016/j.bbrc.2005.02.153

Song, H.-D., Tu, C.-C., Zhang, G.-W., Wang, S.-Y., Zheng, K., Lei, L.-C., Chen, Q.-X., Gao, Y.-W., Zhou, H.-Q., Xiang, H., Zheng, H.-J., Chern, S.-W.W., Cheng, F., Pan, C.-M., Xuan, H., Chen, S.-J., Luo, H.-M., Zhou, D.-H., Liu, Y.-F., He, J.-F., Qin, P.-Z., Li, L.-H., Ren, Y.-Q., Liang, W.-J., Yu, Y.-D., Anderson, L., Wang, M., Xu, R.-H., Wu, X.-W., Zheng, H.-Y., Chen, J.-D., Liang, G., Gao, Y., Liao, M., Fang, L., Jiang, L.-Y., Li, H., Chen, F., Di, B., He, L.-J., Lin, J.-Y., Tong, S., Kong, X., Du, L., Hao, P., Tang, H., Bernini, A., Yu, X.-J., Spiga, O., Guo, Z.-M., Pan, H.-Y., He, W.-Z., Manuguerra, J.-C., Fontanet, A., Danchin, A., Niccolai, N., Li, Y.-X., Wu, C.-I., Zhao, G.-P., 2005. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc. Natl. Acad. Sci. 102, 2430–2435. https://doi.org/10.1073/pnas.0409608102

Song, W., Gui, M., Wang, X., Xiang, Y., 2018. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLOS Pathog. 14, e1007236. https://doi.org/10.1371/journal.ppat.1007236

Sruthi, C.K., Prakash, M.K., 2019. Statistical characteristics of amino acid covariance as possible descriptors of viral genomic complexity. Sci. Rep. 9, 18410. https://doi.org/10.1038/s41598-019-54720-y

Tagliamonte, M.S., Abid, N., Chillemi, G., Salemi, M., Mavian, C., 2020. Re-insights into origin and adaptation of SARS-CoV-2. bioRxiv 2020.03.30.015685. https://doi.org/10.1101/2020.03.30.015685

Tan, Y.-J., 2005. The Severe Acute Respiratory Syndrome (SARS)-coronavirus 3a protein may function as a modulator of the trafficking properties of the spike protein. Virol. J. 2, 5–5. https://doi.org/10.1186/1743-422X-2-5

Tan, Y.-J., Teng, E., Shen, S., Tan, T.H.P., Goh, P.-Y., Fielding, B.C., Ooi, E.-E., Tan, H.-C., Lim, S.G., Hong, W., 2004. A Novel Severe Acute Respiratory Syndrome Coronavirus Protein, U274, Is Transported to the Cell Surface and Undergoes Endocytosis. J. Virol. 78, 6723–6734. https://doi.org/10.1128/JVI.78.13.6723-6734.2004

Walls, A.C., Park, Y.-J., Tortorici, M.A., Wall, A., McGuire, A.T., Veesler, D., 2020. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181, 281-292.e6. https://doi.org/10.1016/j.cell.2020.02.058

Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., Yuan, M.-L., Zhang, Y.-L., Dai, F.-H., Liu, Y., Wang, Q.-M., Zheng, J.-J., Xu, L., Holmes, E.C., Zhang, Y.-Z., 2020. A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269. https://doi.org/10.1038/s41586-0202008-3

Xia, X., 2020. Extreme Genomic CpG Deficiency in SARS-CoV-2 and Evasion of Host Antiviral Defense. Mol. Biol. Evol. https://doi.org/10.1093/molbev/msaa094

Zhang, T., Wu, Q., Zhang, Z., 2020. Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak. Curr. Biol. 30, 1346-1351.e2. https://doi.org/10.1016/j.cub.2020.03.022

Zhong, X., 2006. Amino terminus of the SARS coronavirus protein 3a elicits strong, potentially protective humoral responses in infected patients. J. Gen. Virol. 87, 369–373. https://doi.org/10.1099/vir.0.81078-0

<u>Figure Legend</u>

Figure 1 Force mapping graph showing the relationship between 850 genomes and 197 clusters and residues in each cluster.

Figure 2. Plotting of predicted covariant residues in different CoVs by protein. (A) Mapped covariant residues in 1a/1b polyproteins, S, 3a, E,M, and N proteins from the bat CoVs found in SARS-CoV-2 . Conserved residues found in other groups are mapped as a reference. **(B)** Graph showing a progression of Clusters and residue content more abundant in Bat CoVs to those more restricted in SARS-CoV-2 and closely related viruses. **(C)** Residues found to covary that are restricted to categories. Those with overlap and are conserved are shown as "Conserved A".

Figure 3. Measurement of the frequency of transition and transversion SNPs between SARS-CoV-2, RATG13, and PCoV-GX-P4L. (A) Plots separately showing the frequency of transitions and transversions in SARS-CoV-2, RATG13, and PCoV-GX-P4L. **(B)** The alignment of RATG13 and PCoV-GX-P4L to SARS-CoV-2 within the S RBD domain showing both amino acid and nucleotide identities. Covariant residues are colored red and conserved residues blue. Arrows indicate determined contacts between ACE-2 and RBD residues.

Figure 3A. Frequency of transition and transversion SNPs between genomes

SARS-CoV-2 vs RATG13 — Transition/Transversion Frequency Ratio = 7.5

SARS-CoV-2 vs PCoV_GX-P4L — Transition/Transversion Frequency Ratio = 1.92

RATG13 vs PCoV_GX-P4L — Transition/Transversion Frequency Ratio = 1.98

Figure 3B. Spike RBD region showing SNPs between SARS-CoV-2 and RATG13/PCov_GX-P4L

Red= Covariant

Blue= Conserved SARS-CoV/CoV-2

Purple = Covariant/Conserved

↓ ACE-2 contact

Transition/Transversion Frequency Ratio

SARS-CoV-2:RATG13: 0.90

SARS-CoV-2:PCoV_GX: 0.83

```
                          ↓           ↓               ↓     ↓  ↓
              a gtt   g  aa      g   tt  ac                    gg     t t          a           a
PCoV_GX-P4L   S  V  K  Q  D  A  L  T  G  G  N  Y  G  Y  L  Y  R  L  F  R
              g  c     a        g a    a ag   c              t    c t   t   c c t c c         a
RATG13        S  K  H  I  D  A  K  E  G  G  N  F  N  Y  L  Y  R  L  F  R
              tct aac aat ctt gat tct aag gtt ggt ggt aat tat aat tac ctg tat aga ttg ttt agg
SARS-CoV-2    S  N  N  L  D  S  K  V  G  G  N  Y  N  Y  L  Y  R  L  F  R
              438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457

                                                                              ↓
                g      t       a                      c              a   c   a          c
PCoV_GX-P4L   K  S  K  L  K  P  F  E  R  D  I  S  T  E  I  Y  Q  A  G  S
              a g            t        c           g          c           t   c  a   a     c
RATG13        K  A  N  L  K  P  F  E  R  D  I  S  T  E  I  Y  Q  A  G  S
              aag tct aat ctc aaa cct ttt gag aga gat att tca act gaa atc tat cag gcc ggt agc
SARS-CoV-2    K  S  N  L  K  P  F  E  R  D  I  S  T  E  I  Y  Q  A  G  S
              458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477

                              ↓  ↓        ↓           ↓              ↓
                c       c       caa   tt    c  a            t   a      c t  g   agg              t
PCoV_GX-P4L   T  P  C  N  G  Q  V  G  L  N  C  Y  Y  P  L  E  R  Y  G  F
              a             caa   act    c a      c           ac    a  c t t ag        a       t
RATG13        K  P  C  N  G  Q  T  G  L  N  C  Y  Y  P  L  Y  R  Y  G  F
              aca cct tgt aat ggt gtt gaa ggt ttt aat tgt tac ttt cct tta caa tca tat ggt ttc
SARS-CoV-2    T  P  C  N  G  V  E  G  F  N  C  Y  F  P  L  Q  S  Y  G  F
              478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497

               ↓      ↓  ↓  ↓      ↓
                c   a      ca              aac
PCoV_GX-P4L   H  P  T  T  G  V  N  Y  Q  P
              t c   t      g                  c
RATG13        Y  P  T  D  G  V  G  H  Q  P
              caa ccc act aat ggt gtt ggt tac caa cca
SARS-CoV-2    Q  P  T  N  G  V  G  Y  Q  P
              498 499 500 501 502 503 504 505 506 507
```

Supplemental Figures, Files, and Tables

Supplemental Figure S1. Phylogeny of the 850 CoVs. Maximum Likelihood Tree using the aligned amino acids from 1a/1b, S, 3a, M, E, and N proteins from bat, pangolin, civet, and human CoVs.

Supplemental Figure S2. Alignment of covariants with the S receptor-binding domain. Aligned SAS-CoV and SARS-CoV2 sequences in the Spike RBD showing sequence conservation (blue), covariant residues in SARS-CoV-2 (red arrows), contacts with ACE-2, and contacts between Ab R80 and SARS-CoV.

Supplemental Figure S3. Plotting of predicted covariant and interacting residues in clinical strains and highlighted residues in S (A) 796 Covarying residue pairs detected in the clinical isolates. Abundance is indicated by hue. High abundance is that both residues vary in at least 4% in the population, mid-abundance is that least on residue is varied at least 4%, and low-abundance is that neither less vary than 4%. Overlap pairs are those covariant residues detected in both the 850 CoVs and the clinical strains. **(B)** Residues predicted to interact within the S protein from the PDB (6VXX) are orange. Residue linkages with S 614 and S and 3a proteins in the SAR-CoV2 clusters are indicated in dark blue. The Location of residues identified in this work as emerging in both SARS-CoV and SARS-CoV2 are circled in black.

Supplemental Figure S4. Covariant residues in 3a domains and observed variance in the 3a ectodomain. (A) Diagram showing the positions of extracellular, cytoplasmic, and transmembrane domains (TMD). Red arrows indicate covariant residues from 850 CoVs and blue and purple arrows are those from clinical strains as shows in Supplemental S3. **(B)** Comparison of SARS-CoV-2 and SARS-CoV residues in the 3a N-terminal ectodomain and arrows from (A) showing covariance. Distinct residues are colored blue. **(C)** The consensus sequence of 3a derived from the alignment of CoVs in this work and all different substitutions observed each position. Variable residues are colored red. **(D)** BepiPred-2.0 epitope prediction using residues in the 3a ectodomain.

Supplemental Figure S5. Covariants that emerged during SARS-CoV and SARS-CoV2. (A) Gephi Force map inset showing Cluster 126 and highlighted genomes that possess the Cluster 126 residues. The ML phylogenic tree showing the relative relationship of circled strains is included as a reference. **(B)** Alignment of strains to both SARS-CoV and SARS-CoV2 showing the order and diversity of these 8 residues in S protein. **(C)** Structures of both SARS-CoV2 (PDB 6VXX) and SARS-CoV2 (6ACC) showing highlighted residues belonging to both. Q23 is missing from the SARS-CoV2 and the closest residue A27 was labeled to provide an approximate location.

Supplemental File F1. Gephi Force-Mapping File

Supplemental Table S1. Accession numbers and description of all genomes used in this work

Supplemental Table S2. Raw Covariance data and coordinates in both 850 CoV consensus and equivalent in SARS-CoV2. Amino acid positions are the best approximate based on alignment.

Supplemental Table S3. Cluster, Genome, and Residue linkage data used for force mapping.

Supplemental Table S4. Residue data by cluster used to chart Bat CoV and SARS-CoV-2 progression

Supplemental Table S5. 1231 Covariant residues in SARS-CoV-2, SARS-CoV Bat, Pangolin, and Civet. Residues in the 850 CoV consensus and approximate positions in the SARS-CoV-2 proteins are indicated.

Supplemental Table S6. Raw clinical pairwise covariance data and positions of residues in proteins.

Supplemental Figure 1

Supplemental 2

Covariant   ↓↓ ↓ ↓↓↓↓   ↓   ↓ ↓↓↓↓ ↓   ↓ ↓
ACE-2 contact   ↓   ↓   ↓ ↓↓
SARS-CoV-2 [438]SN**N**LDSKVG**GNYNY**L**YR**LFRKSN**L**K**PFERDIS**TEI
SARS-CoV   [425]TR**N**IDATST**GNYNY**K**YR**YLRHGK**L**R**PFERDIS**NVP
Ab 80R   ●   ●● ●   ●   ●   ●

Covariant   ↓↓↓ ↓   ↓↓ ↓↓↓↓ ↓   ↓↓   ↓↓ ↓↓ ↓
ACE-2 contact   ↓   ↓↓ ↓   ↓ ↓ ↓ ↓↓↓ ↓
SARS-CoV-2 [473]YQAGST**PC**NGVEGF**NCY**F**PL**QS**YGF**QP**T**NGVG**YQP**
SARS-CoV   [460]FSPDGK**PC**TP-PAL**NCY**W**PL**ND**YGF**YT**T**TGIG**YQP**
Ab 80R   ● ●●● ●●● ●●● ● ●

Supplemental Figure 3A

Supplemental Figure 3B

Supplemental 4A

3a[13]
Spike[614]
RdRp[335]

3a[57]
Nsp2[588]
Nsp6[48]

3a[69]
Nsp2[190]

3a[93]
Nsp2[215]

3a[219]
Nsp3[45]

3a[251]
Nsp6[48]

TMD   TMD   TMD

1   275

Extracellular
NTD Domain

Extracellular

CTD covarying domain

Supplemental 4B

```
                    +1
SARS-CoV2 MDLFMRIFTIGTVTLKQ-GEIK-D ATPSDFVRATATIPIQASLPFGW
SARS-CoV  MDLFMRFFTLGSIT-AQ--PVKIDNASPASTVHATATIPLQASLPFGW
```

Supplemental 4C

```
                    +1
Consensus MDLFMRIFTIGTVTLKQPGEIKIDNATPSDFVRATATIPIQASLPFGW
             SF  L SIS-RR--PSQ-E- SLTSTIHT       L   TFS R
             A     AH  SG  N  F ANS
                       V
                       A
```

Variable
Residues

Supplemental 4D

```
Consensus MDLFMRIFTIGTVTLKQPGEIKIDNATPSDFVRATATIPIQ
             +1
SARS-CoV2 MDLFMRIFTIGTVTLKQ-GEIK-D ATPSDFVRATATIPIQ
```

Supplemental Figure 5A

Cluster 126 (8 Spike residues)

SARS-Cov2

Cluster 126

SARS-CoV

HumanCov2
bat
civet
human
pangolin

0.120

Supplemental Figure 5B

```
                              Signal Sequence              Corresponding AA Positions
SARS 2003/4                         ↓                         1-23:54:66:153:213
BatCoVWIV16         M----FI-F-L--F-FL---T--LTSG-S-DLES--C-----TTFDDV--Q:L:H:T:V
CivetCoV020         M----FI-F-L--L-FL---T--LTSG-S-DLDR--C-----TTFDDV--Q:L:H:M:V
SARS-CoV            M----FI-F-L--L-FL---T--LTSG-S-DLDR--C-----TTFDDV--Q:L:H:M:V

Unrelated BatCoV (2013)- Typical of most CoVs in homology

BatCoVYN2013        MLI--L--FVF--L------P--FIAA-----DT--C-----LNFTNL-AA:Y:F:-:V

SARS-CoV2 (2019/2020)

BatCoV|ZXC21        ML---F--F-L-FL-QF---A--LVN--S----Q--C--D-LTG--RT--P:Y:Y:-:N
BatCoV|ZC45         ML---F--F-L-FL-QF---A--LVN--S----Q--C-VN-LTG--RT--P:Y:Y:-:N
Pangolin|GX-P5L     M----FV-F-LFVL-----P--LVS--S----Q--C-VN-LTT--RT--G:L:N:V:V
BatCoV|RATG13       M----FV-F-L-VL--L---P--LVS--S----Q--C-VN-LTT--RT--Q:L:H:M:V
SARS-CoV2           M----FV-F-L-VL-L---P--LVS--S----Q--C-VN-LTT--RT--Q:L:H:M:V
```

Supplemental Figure 5C

SARS-CoV2 [H66,V213]
Q23 missing (A27 colored to show proximity)

SARS-CoV [Q23(Q26),H66(H70),V213(V206)]
SARS-CoV residues shown in parenthesis

PDB 6VXX

PDB 6ACC

Overview of Generated Data and Figures

850 CoV Genome Sequences
Align 1a/1b, Spike, 3a, E, M, and N

DNA sequences
SARS-CoV-2, RATG13,
and PCoV-GX-P4L

Phylogeny
Supplemental S1

Covariance Analysis

Alignment and quantification
of transitions/transversion
Main Figure 3

Force Mapping
Figure 1
Supplemental Table S2
Supplemental F1
Website

Binning of Residues

Bat to Human
Analysis
Figure 2a
Supplemental Table S3

Covariants

Restricted Covariants
by Host
Figure 2b
Supplemental Table S4

13,611 Clinical Samples

Compare Clinical and Covariants

Compare Clinicals
Figure 3a
Supplemental S3

Compare Clinicals to
conserved stucture in Spike and
3a, reference human specific
Cluster 126
Figure 3b
Supplemental Figures S2,S3,S4
Supplemental Figure S5